MUC5AC and asthma: Examination of bronchial biopsies from 10 moderate‐severe asthma patients treated 250 mg daily open‐label AZM (Zithromax, Pfizer Inc.)for 6 weeks did not identify any significant change in: (1) bronchial epithelial cell thickness, (2) mucin production (% goblet cells), and (3) MMP‐9 production (bronchial wash) when pre‐ and post‐AZM samples were compared.